CytoDyn (STU:296) Cyclically Adjusted PB Ratio: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:296 CytoDyn Inc STU:296
34 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is CytoDyn Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CytoDyn  (STU:296) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CytoDyn Cyclically Adjusted PB Ratio Related Terms


CytoDyn Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for CytoDyn's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Cyclically Adjusted PB Ratio Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:296 vs BCYC, ALXO, SABS: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, CytoDyn's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's Cyclically Adjusted PB Ratio falls into.


STU:296
34GF Score
CytoDyn Inc STU:296
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CytoDyn's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2026 is calculated as:

For example, CytoDyn's adjusted Book Value per Share data for the three months ended in Feb. 2026 was:

Adj_Book=Book Value per Share/CPI of Feb. 2026 (Change)*Current CPI (Feb. 2026)
=-0.065/326.7850*326.7850
=-0.065

Current CPI (Feb. 2026) = 326.7850.

CytoDyn Quarterly Data

Book Value per Share CPI Adj_Book
201605 0.073 240.229 0.099
201608 0.045 240.849 0.061
201611 0.036 241.353 0.049
201702 0.034 243.603 0.046
201705 -0.007 244.733 -0.009
201708 -0.046 245.519 -0.061
201711 -0.066 246.669 -0.087
201802 -0.029 248.991 -0.038
201805 -0.051 251.588 -0.066
201808 -0.073 252.146 -0.095
201811 -0.024 252.038 -0.031
201902 -0.018 252.776 -0.023
201905 -0.024 256.092 -0.031
201908 -0.016 256.558 -0.020
201911 -0.031 257.208 -0.039
202002 -0.009 258.678 -0.011
202005 -0.004 256.394 -0.005
202008 0.004 259.918 0.005
202011 -0.009 260.229 -0.011
202102 -0.021 263.014 -0.026
202105 -0.028 269.195 -0.034
202108 -0.033 273.567 -0.039
202111 -0.016 277.948 -0.019
202202 -0.028 283.716 -0.032
202205 -0.124 292.296 -0.139
202208 -0.115 296.171 -0.127
202211 -0.138 297.711 -0.151
202302 -0.119 300.840 -0.129
202305 -0.110 304.127 -0.118
202308 -0.115 307.026 -0.122
202311 -0.109 307.051 -0.116
202402 -0.112 310.326 -0.118
202405 -0.102 314.069 -0.106
202408 -0.063 314.796 -0.065
202411 -0.069 315.493 -0.071
202502 -0.072 319.082 -0.074
202505 -0.068 321.465 -0.069
202508 -0.068 323.976 -0.069
202511 -0.082 324.122 -0.083
202602 -0.065 326.785 -0.065

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
34GF Score

Get the complete analysis for STU:296

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price